[1] 刘迎丽,王军.复方苦参注射液配合化疗治疗晚期胃癌的疗效观察[J].中国医药导刊,2014,16(4):683-684. [2] 宁四清,徐海声,杨超.复方苦参注射液联合FOLFOX4化疗方案治疗晚期胃癌的临床研究[J].现代药物与临床,2015,30(3):47-50. [3] Satoh T,Xu RH,Chung HC,et al.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations:TyTAN-a randomized,phase Ⅲ study[J].J Clin Oncol,2014,32(19):2039-2049. [4] 韩芬叶.替吉奥联合奥沙利铂用于胃癌根治术后辅助化疗的安全性分析及护理[J].实用临床医药杂志,2014,18(18):33-35. [5] 杨立平,徐亚琨.复方苦参注射液对胃癌患者化疗药物不良反应的影响[J].中国药房,2014,25(28):2626-2628. [6] Hironaka S,Ueda S,Yasui H,et al.Randomized,open-label,phase Ⅲ study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum:WJOG 4007 trial[J].J Clin Oncol,2013,31(35):4438-4444. [7] 朱俊,林俊,陈善明,等.复方苦参注射液辅助化疗对晚期胃癌的疗效观察[J].中国药师,2015,18(12):2117-2119. [8] Kang YK,Rha SY,Tassone P,et al.A phase Ⅱa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab,capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer[J].Br J Cancer,2014,111(4):660-666. [9] 齐宏,毛伟征,马贵亮.TNF-α联合奥沙利铂对胃癌细胞SGC-7901抑制作用的研究[J].中国现代普通外科进展,2013,16(5):337-341. [10] 许进秀,赵世叶,王爱蓉,等.复方苦参注射液联合FOLFOX方案治疗晚期胃癌的临床观察[J].中华中医药学刊,2013,31(8):1812-1815. [11] 朴瑛,郑振东,唐玲,等.替吉奥联合复方苦参注射液治疗老年晚期胃癌的疗效和安全性分析[J].临床肿瘤学杂志,2016,21(6):535-539. [12] 闫卿,刘全华,尹宜发.复方苦参注射液联合奥沙利铂治疗直肠癌疗效观察[J].现代中西医结合杂志,2015,24(31):3488-3489. [13] 吴驻林,谭婉君,连宝涛,等.复方苦参注射液联合含奥沙利铂化疗方案治疗大肠癌疗效与安全性的系统评价[J].中国药房,2017,28(3):369-373.
2018, Vol. 35 
